<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2066">
  <stage>Registered</stage>
  <submitdate>5/08/2008</submitdate>
  <approvaldate>5/08/2008</approvaldate>
  <nctid>NCT00730977</nctid>
  <trial_identification>
    <studytitle>A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device</studytitle>
    <scientifictitle>A Pilot Study to Investigate the Tolerability of Inhaled Dry Powder Mannitol (IDPM) Administered Via a Novel Dry Powder Inhaler Device in Healthy Individuals and Subjects With Bronchiectasis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DPM-DEV-101b</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
    <healthcondition>Bronchiectasis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - dry powder inhaled mannitol

Experimental: single - single arm, open label, 4 doses tested.


Treatment: drugs: dry powder inhaled mannitol
single doses of 40 mg, 70 mg and 100 mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>tolerability</outcome>
      <timepoint>immediately and 10 mins post dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>respiratory symptoms, FEV1</outcome>
      <timepoint>pre-dose, immediately and 10 mins post dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  healthy or bronchiectatic; 18 years and over</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  uncontrolled asthma, unstable</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>15</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmaxis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A novel dry powder inhaler device will be used to administer mannitol to healthy subjects and
      subjects with bronchiectasis in single doses higher than previously given.The main objective
      is to assess tolerability of these doses using the new device.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00730977</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>